Piramal Alternatives invests Rs 110 crore in Biodeal Pharmaceuticals

Piramal Alternatives invested Rs 110 crore in Noida-based Biodeal Pharmaceuticals through convertible instruments. The funding will enhance infrastructure, technology, and a nutraceuticals manufacturing facility. Biodeal is a key contract manufacturing player, specializing in nasal sprays and achieving PIC/S approval.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZCndIl6
via IFTTT